Macrophage PPARγ inhibits GPR132 to mediate the anti-tumor effects of rosiglitazone

eLife

Volumn 5, Issue OCTOBER2016, 2016, Pages

  Cheng, Wing Yin ^a   Huynh, Hoangdinh ^a   Chen, Peiwen ^a   Penã Llopis, Samuel ^a   Wan, Yihong ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 9; CYCLIN D1; CYCLOOXYGENASE 2; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 132; GELATINASE B; INTERLEUKIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN BAX; ROSIGLITAZONE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTINEOPLASTIC AGENT; CELL CYCLE PROTEIN; G2A RECEPTOR;

ANIMAL CELL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE CONTROL; GENE DELETION; GENE EXPRESSION; GENE REPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LOSS OF FUNCTION MUTATION; LUCIFERASE ASSAY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENE INACTIVATION; GENETICS; KNOCKOUT MOUSE; MACROPHAGE; MAMMARY NEOPLASMS, EXPERIMENTAL; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE PROTEINS; GENE KNOCKOUT TECHNIQUES; MACROPHAGES; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, KNOCKOUT; PPAR GAMMA; RECEPTORS, G-PROTEIN-COUPLED; THIAZOLIDINEDIONES;

EID: 84990191238     PISSN: None     EISSN: 2050084X     Source Type: Journal    
DOI: 10.7554/eLife.18501     Document Type: Article

References (76)

1. Ahmadian M, Suh JM, Hah N, Liddle C, Atkins AR, Downes M, Evans RM. 2013. PPARg signaling and metabolism: the good, the bad and the future. Nature Medicine 19:557–566. doi: 10.1038/nm.3159
2. Aldred MA, Morrison C, Gimm O, Hoang-Vu C, Krause U, Dralle H, Jhiang S, Eng C. 2003. Peroxisome proliferator-activated receptor gamma is frequently downregulated in a diversity of sporadic nonmedullary thyroid carcinomas. Oncogene 22:3412–3416. doi: 10.1038/sj.onc.1206400
3. Apostoli AJ, Roche JM, Schneider MM, SenGupta SK, Di Lena MA, Rubino RE, Peterson NT, Nicol CJ. 2015. Opposing roles for mammary epithelial-specific PPARg signaling and activation during breast tumour progression. Molecular Cancer 14:85. doi: 10.1186/s12943-015-0347-8
4. Babaev VR, Yancey PG, Ryzhov SV, Kon V, Breyer MD, Magnuson MA, Fazio S, Linton MF. 2005. Conditional knockout of macrophage PPARgamma increases atherosclerosis in C57BL/6 and low-density lipoprotein receptor-deficient mice. Arteriosclerosis, Thrombosis, and Vascular Biology 25:1647–1653. doi: 10.1161/01. ATV.0000173413.31789.1a
5. Barlic J, Zhang Y, Foley JF, Murphy PM. 2006. Oxidized lipid-driven chemokine receptor switch, CCR2 to CX3CR1, mediates adhesion of human macrophages to coronary artery smooth muscle cells through a peroxisome proliferator-activated receptor gamma-dependent pathway. Circulation 114:807–819. doi: 10. 1161/CIRCULATIONAHA.105.602359
6. Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB, Derr RL, Wolff AC, Brancati FL. 2010. Postoperative mortality in cancer patients with preexisting diabetes: systematic review and meta-analysis. Diabetes Care 33: 931–939. doi: 10.2337/dc09-1721
7. Bingle L, Brown NJ, Lewis CE. 2002. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. The Journal of Pathology 196:254–265. doi: 10.1002/path.1027
8. Biswas T, Gu X, Yang J, Ellies LG, Sun LZ. 2014. Attenuation of TGF-b signaling supports tumor progression of a mesenchymal-like mammary tumor cell line in a syngeneic murine model. Cancer Letters 346:129–138. doi: 10. 1016/j.canlet.2013.12.018
9. Blaser MJ, Chyou PH, Nomura A. 1995. Age at establishment of Helicobacter pylori infection and gastric carcinoma, gastric ulcer, and duodenal ulcer risk. Cancer Research 55:562–565
10. Bosetti C, Rosato V, Buniato D, Zambon A, La Vecchia C, Corrao G. 2013. Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis. The Oncologist 18:148–156. doi: 10.1634/ theoncologist.2012-0302
11. Burstein HJ, Demetri GD, Mueller E, Sarraf P, Spiegelman BM, Winer EP. 2003. Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study. Breast Cancer Research and Treatment 79:391–397. doi: 10.1023/A:1024038127156
12. Cancer Genome Atlas Network. 2012. Comprehensive molecular portraits of human breast tumours. Nature 490:61–70. doi: 10.1038/nature11412
13. Casey AE, Laster WR, Ross GL. 1951. Sustained enhanced growth of carcinoma EO771 in C57 black mice. Experimental Biology and Medicine 77:358–362. doi: 10.3181/00379727-77-18779
14. Chawla A, Boisvert WA, Lee CH, Laffitte BA, Barak Y, Joseph SB, Liao D, Nagy L, Edwards PA, Curtiss LK, Evans RM, Tontonoz P. 2001. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Molecular Cell 7:161–171. doi: 10.1016/S1097-2765(01)00164-2
15. Chen Y, Green SR, Ho J, Li A, Almazan F, Quehenberger O. 2005. The mouse CCR2 gene is regulated by two promoters that are responsive to plasma cholesterol and peroxisome proliferator-activated receptor gamma ligands. Biochemical and Biophysical Research Communications 332:188–193. doi: 10.1016/j.bbrc.2005.04.110
16. Clausen BE, Burkhardt C, Reith W, Renkawitz R, Förster I. 1999. Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Research 8:265–277. doi: 10.1023/A:1008942828960
17. Coussens LM, Werb Z. 2002. Inflammation and cancer. Nature 420:860–867. doi: 10.1038/nature01322
18. Drzewoski J, Drozdowska A, Sliwińska A. 2011. Do we have enough data to confirm the link between antidiabetic drug use and cancer development? Polskie Archiwum Medycyny Wewnetrznej 121:81–87
19. Engblom C, Pfirschke C, Pittet MJ. 2016. The role of myeloid cells in cancer therapies. Nature Reviews Cancer 16:447–462. doi: 10.1038/nrc.2016.54
20. Feng YH, Velazquez-Torres G, Gully C, Chen J, Lee MH, Yeung SC. 2011. The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth. Journal of Cellular and Molecular Medicine 15:825–836. doi: 10.1111/ j.1582-4934.2010.01083.x
21. Fenner MH, Elstner E. 2005. Peroxisome proliferator-activated receptor-gamma ligands for the treatment of breast cancer. Expert Opinion on Investigational Drugs 14:557–568. doi: 10.1517/13543784.14.6.557
22. Fröhlich E, Wahl R. 2015. Chemotherapy and chemoprevention by thiazolidinediones. BioMed Research International 2015:845340. doi: 10.1155/2015/845340
23. Goetze S, Bungenstock A, Czupalla C, Eilers F, Stawowy P, Kintscher U, Spencer-Hänsch C, Graf K, Nürnberg B, Law RE, Fleck E, Gräfe M. 2002. Leptin induces endothelial cell migration through Akt, which is inhibited by PPARgamma-ligands. Hypertension 40:748–754. doi: 10.1161/01.HYP.0000035522.63647.D3
24. Han KH, Chang MK, Boullier A, Green SR, Li A, Glass CK, Quehenberger O. 2000. Oxidized LDL reduces monocyte CCR2 expression through pathways involving peroxisome proliferator-activated receptor gamma. Journal of Clinical Investigation 106:793–802. doi: 10.1172/JCI10052
25. He W, Barak Y, Hevener A, Olson P, Liao D, Le J, Nelson M, Ong E, Olefsky JM, Evans RM. 2003. Adipose- specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle. PNAS 100:15712–15717. doi: 10.1073/pnas.2536828100
26. Hevener AL, Olefsky JM, Reichart D, Nguyen MT, Bandyopadyhay G, Leung HY, Watt MJ, Benner C, Febbraio MA, Nguyen AK, Folian B, Subramaniam S, Gonzalez FJ, Glass CK, Ricote M. 2007. Macrophage PPAR gamma is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones. Journal of Clinical Investigation 117:1658–1669. doi: 10.1172/JCI31561
27. Justus CR, Dong L, Yang LV. 2013. Acidic tumor microenvironment and pH-sensing G protein-coupled receptors. Frontiers in Physiology 4:354. doi: 10.3389/fphys.2013.00354
28. Kabarowski JH. 2009. G2A and LPC: regulatory functions in immunity. Prostaglandins & Other Lipid Mediators 89:73–81. doi: 10.1016/j.prostaglandins.2009.04.007
29. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordón-Cardo C, Guise TA, Massagué J. 2003. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3:537–549. doi: 10.1016/S1535- 6108(03)00132-6
30. Keshamouni VG, Arenberg DA, Reddy RC, Newstead MJ, Anthwal S, Standiford TJ. 2005. PPAR-gamma activation inhibits angiogenesis by blocking ELR+CXC chemokine production in non-small cell lung cancer. Neoplasia 7:294–301. doi: 10.1593/neo.04601
31. Kisanuki YY, Hammer RE, Miyazaki J, Williams SC, Richardson JA, Yanagisawa M. 2001. Tie2-Cre transgenic mice: a new model for endothelial cell-lineage analysis in vivo. Developmental Biology 230:230–242. doi: 10. 1006/dbio.2000.0106
32. Komohara Y, Jinushi M, Takeya M. 2014. Clinical significance of macrophage heterogeneity in human malignant tumors. Cancer Science 105:1–8. doi: 10.1111/cas.12314
33. Krzeszinski JY, Wan Y. 2015. New therapeutic targets for cancer bone metastasis. Trends in Pharmacological Sciences 36:360–373. doi: 10.1016/j.tips.2015.04.006
34. Kumar AP, Quake AL, Chang MK, Zhou T, Lim KS, Singh R, Hewitt RE, Salto-Tellez M, Pervaiz S, Cle´ ment MV. 2009. Repression of NHE1 expression by PPARgamma activation is a potential new approach for specific inhibition of the growth of tumor cells in vitro and in vivo. Cancer Research 69:8636–8644. doi: 10.1158/0008- 5472.CAN-09-0219
35. Kuper H, Adami HO, Trichopoulos D. 2000. Infections as a major preventable cause of human cancer. Journal of Internal Medicine 248:171–183. doi: 10.1046/j.1365-2796.2000.00742.x
36. Larson SD, Jackson LN, Chen LA, Rychahou PG, Evers BM. 2007. Effectiveness of siRNA uptake in target tissues by various delivery methods. Surgery 142:262–269. doi: 10.1016/j.surg.2007.03.011
37. Le LQ, Kabarowski JH, Weng Z, Satterthwaite AB, Harvill ET, Jensen ER, Miller JF, Witte ON. 2001. Mice lacking the orphan G protein-coupled receptor G2A develop a late-onset autoimmune syndrome. Immunity 14:561–571. doi: 10.1016/S1074-7613(01)00145-5
38. Lefterova MI, Haakonsson AK, Lazar MA, Mandrup S. 2014. PPARg and the global map of adipogenesis and beyond. Trends in Endocrinology & Metabolism 25:293–302. doi: 10.1016/j.tem.2014.04.001
39. Lelekakis M, Moseley JM, Martin TJ, Hards D, Williams E, Ho P, Lowen D, Javni J, Miller FR, Slavin J, Anderson RL. 1999. A novel orthotopic model of breast cancer metastasis to bone. Clinical & Experimental Metastasis 17: 163–170. doi: 10.1023/A:1006689719505
40. Lin EY, Nguyen AV, Russell RG, Pollard JW. 2001. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. Journal of Experimental Medicine 193:727–740. doi: 10.1084/jem.193.6.727
41. Monami M, Dicembrini I, Mannucci E. 2014. Thiazolidinediones and cancer: results of a meta-analysis of randomized clinical trials. Acta Diabetologica 51:91–101. doi: 10.1007/s00592-013-0504-8
42. Monami M, Lamanna C, Marchionni N, Mannucci E. 2008. Rosiglitazone and risk of cancer: a meta-analysis of randomized clinical trials. Diabetes Care 31:1455–1460. doi: 10.2337/dc07-2308
43. Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M, Fletcher C, Singer S, Spiegelman BM. 1998. Terminal differentiation of human breast cancer through PPAR gamma. Molecular Cell 1:465–470. doi: 10. 1016/S1097-2765(00)80047-7
44. Mueller E, Smith M, Sarraf P, Kroll T, Aiyer A, Kaufman DS, Oh W, Demetri G, Figg WD, Zhou XP, Eng C, Spiegelman BM, Kantoff PW. 2000. Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. PNAS 97:10990–10995. doi: 10.1073/pnas.180329197
45. Noy R, Pollard JW. 2014. Tumor-associated macrophages: from mechanisms to therapy. Immunity 41:49–61. doi: 10.1016/j.immuni.2014.06.010
46. Odegaard JI, Ricardo-Gonzalez RR, Goforth MH, Morel CR, Subramanian V, Mukundan L, Red Eagle A, Vats D, Brombacher F, Ferrante AW, Chawla A. 2007. Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature 447:1116–1120. doi: 10.1038/nature05894
47. Park J, Morley TS, Kim M, Clegg DJ, Scherer PE. 2014. Obesity and cancer–mechanisms underlying tumour progression and recurrence. Nature Reviews Endocrinology 10:455–465. doi: 10.1038/nrendo.2014.94
48. Qian BZ, Pollard JW. 2010. Macrophage diversity enhances tumor progression and metastasis. Cell 141:39–51. doi: 10.1016/j.cell.2010.03.014
49. Radu CG, Yang LV, Riedinger M, Au M, Witte ON. 2004. T cell chemotaxis to lysophosphatidylcholine through the G2A receptor. PNAS 101:245–250. doi: 10.1073/pnas.2536801100
50. Richardson LC, Pollack LA. 2005. Therapy insight: Influence of type 2 diabetes on the development, treatment and outcomes of cancer. Nature Clinical Practice Oncology 2:48–53. doi: 10.1038/ncponc0062
51. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. 1998. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391:79–82. doi: 10.1038/34178
52. Ruffell B, Affara NI, Coussens LM. 2012. Differential macrophage programming in the tumor microenvironment. Trends in Immunology 33:119–126. doi: 10.1016/j.it.2011.12.001
53. Ruffell B, Coussens LM. 2015. Macrophages and therapeutic resistance in cancer. Cancer Cell 27:462–472. doi: 10.1016/j.ccell.2015.02.015
54. Saez E, Rosenfeld J, Livolsi A, Olson P, Lombardo E, Nelson M, Banayo E, Cardiff RD, Izpisua-Belmonte JC, Evans RM. 2004. PPAR gamma signaling exacerbates mammary gland tumor development. Genes & Development 18:528–540. doi: 10.1101/gad.1167804
55. Saez E, Tontonoz P, Nelson MC, Alvarez JG, Ming UT, Baird SM, Thomazy VA, Evans RM. 1998. Activators of the nuclear receptor PPARgamma enhance colon polyp formation. Nature Medicine 4:1058–1061. doi: 10.1038/ 2042
56. Sarraf P, Mueller E, Smith WM, Wright HM, Kum JB, Aaltonen LA, de la Chapelle A, Spiegelman BM, Eng C. 1999. Loss-of-function mutations in PPAR gamma associated with human colon cancer. Molecular Cell 3:799–804. doi: 10.1016/S1097-2765(01)80012-5
57. Scholl SM, Pallud C, Beuvon F, Hacene K, Stanley ER, Rohrschneider L, Tang R, Pouillart P, Lidereau R. 1994. Anti-colony-stimulating factor-1 antibody staining in primary breast adenocarcinomas correlates with marked inflammatory cell infiltrates and prognosis. Journal of the National Cancer Institute 86:120–126. doi: 10.1093/ jnci/86.2.120
58. Scoditti E, Massaro M, Carluccio MA, Distante A, Storelli C, De Caterina R. 2010. PPARgamma agonists inhibit angiogenesis by suppressing PKCalpha- and CREB-mediated COX-2 expression in the human endothelium. Cardiovascular Research 86:302–310. doi: 10.1093/cvr/cvp400
59. Shacter E, Weitzman SA. 2002. Chronic inflammation and cancer. Oncology 16:217–226. doi: 10.1159/ 000218263
60. Shah YM, Morimura K, Gonzalez FJ. 2007. Expression of peroxisome proliferator-activated receptor-g in macrophage suppresses experimentally induced colitis. AJP: Gastrointestinal and Liver Physiology 292:G657–666. doi: 10.1152/ajpgi.00381.2006
61. Skelhorne-Gross G, Reid AL, Apostoli AJ, Di Lena MA, Rubino RE, Peterson NT, Schneider M, SenGupta SK, Gonzalez FJ, Nicol CJ. 2012. Stromal adipocyte PPARg protects against breast tumorigenesis. Carcinogenesis 33:1412–1420. doi: 10.1093/carcin/bgs173
62. Smith U, Gale EA. 2009. Does diabetes therapy influence the risk of cancer? Diabetologia 52:1699–1708. doi: 10. 1007/s00125-009-1441-5
63. Smith U, Gale EA. 2010. Cancer and diabetes: are we ready for prime time? Diabetologia 53:1541–1544. doi: 10. 1007/s00125-010-1815-8
64. Srivastava N, Kollipara RK, Singh DK, Sudderth J, Hu Z, Nguyen H, Wang S, Humphries CG, Carstens R, Huffman KE, DeBerardinis RJ, Kittler R. 2014. Inhibition of cancer cell proliferation by PPARg is mediated by a metabolic switch that increases reactive oxygen species levels. Cell Metabolism 20:650–661. doi: 10.1016/j.cmet.2014.08. 003
65. Straus DS, Glass CK. 2007. Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends in Immunology 28:551–558. doi: 10.1016/j.it.2007.09.003
66. Su S, Liu Q, Chen J, Chen J, Chen F, He C, Huang D, Wu W, Lin L, Huang W, Zhang J, Cui X, Zheng F, Li H, Yao H, Su F, Song E. 2014. A positive feedback loop between mesenchymal-like cancer cells and macrophages is essential to breast cancer metastasis. Cancer Cell 25:605–620. doi: 10.1016/j.ccr.2014.03.021
67. Tontonoz P, Singer S, Forman BM, Sarraf P, Fletcher JA, Fletcher CD, Brun RP, Mueller E, Altiok S, Oppenheim H, Evans RM, Spiegelman BM. 1997. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. PNAS 94:237–241. doi: 10. 1073/pnas.94.1.237
68. Uray IP, Rodenberg JM, Bissonnette RP, Brown PH, Mancini MA. 2012. Cancer-preventive rexinoid modulates neutral lipid contents of mammary epithelial cells through a peroxisome proliferator-activated receptor g- dependent mechanism. Molecular Pharmacology 81:228–238. doi: 10.1124/mol.111.072967
69. Vangaveti V, Baune BT, Kennedy RL. 2010. Hydroxyoctadecadienoic acids: novel regulators of macrophage differentiation and atherogenesis. Therapeutic Advances in Endocrinology and Metabolism 1:51–60. doi: 10. 1177/2042018810375656
70. Wan Y, Chong LW, Evans RM. 2007a. PPAR-gamma regulates osteoclastogenesis in mice. Nature Medicine 13: 1496–1503. doi: 10.1038/nm1672
71. Wan Y, Saghatelian A, Chong LW, Zhang CL, Cravatt BF, Evans RM. 2007b. Maternal PPAR gamma protects nursing neonates by suppressing the production of inflammatory milk. Genes & Development 21:1895–1908. doi: 10.1101/gad.1567207
72. Welch JS, Ricote M, Akiyama TE, Gonzalez FJ, Glass CK. 2003. PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages. PNAS 100:6712–6717. doi: 10.1073/pnas.1031789100
73. Weng Z, Fluckiger AC, Nisitani S, Wahl MI, Le LQ, Hunter CA, Fernal AA, Le Beau MM, Witte ON. 1998. A DNA damage and stress inducible G protein-coupled receptor blocks cells in G2/M. PNAS 95:12334–12339. doi: 10. 1073/pnas.95.21.12334
74. Yang LV, Radu CG, Wang L, Riedinger M, Witte ON. 2005. Gi-independent macrophage chemotaxis to lysophosphatidylcholine via the immunoregulatory GPCR G2A. Blood 105:1127–1134. doi: 10.1182/blood- 2004-05-1916
75. Zhang QW, Liu L, Gong CY, Shi HS, Zeng YH, Wang XZ, Zhao YW, Wei YQ. 2012. Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. PLoS One 7:e50946. doi: 10. 1371/journal.pone.0050946
76. Zhou W, Fong MY, Min Y, Somlo G, Liu L, Palomares MR, Yu Y, Chow A, O’Connor ST, Chin AR, Yen Y, Wang Y, Marcusson EG, Chu P, Wu J, Wu X, Li AX, Li Z, Gao H, Ren X, et al. 2014. Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis. Cancer Cell 25:501–515. doi: 10.1016/j.ccr.2014.03.007